Angiogenic markers in plasma cell myeloma patients treated with novel agents

Anticancer Research

Volumn 35, Issue 2, 2015, Pages 1085-1090

  Medinger, Michael ^a   Halter, Jörg ^a   Heim, Dominik ^a   Buser, Andreas ^a   Gerull, Sabine ^a   Stern, Martin ^a   Passweg, Jakob ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Angiogenesis; Bortezomib; Immunomodulatory drugs; Plasma cell myeloma; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN 2; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FIBROBLAST GROWTH FACTOR 2; IMMUNOMODULATING AGENT; INTERLEUKIN 6; LENALIDOMIDE; MELPHALAN; NEUROPILIN 1; PLACENTAL GROWTH FACTOR; PREDNISONE; SCATTER FACTOR; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; BIOLOGICAL MARKER;

ADULT; ADVANCED CANCER; AGED; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; DISEASE MARKER; FEMALE; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; TREATMENT RESPONSE; ADOLESCENT; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY);

ADOLESCENT; AGED; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84922896136     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P and Palumbo A; European Myeloma Network: European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 99: 232-242, 2014.
2. Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C and Facon T; FIRST Trial Team: Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 371: 906-917, 2014.
3. Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M, Tacchetti P, Zamagni E, Attal M, Lokhorst HM, Desai A, Cakana A, Liu K, van de Velde H, Esseltine DL and Moreau P: Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 31: 3279-3287, 2013.
4. Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG and Anderson KC: Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 66: 184-191, 2006.
5. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris Fand Dammacco F: Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87: 503-508, 1994.
6. Vacca A, Ria R, Reale A and Ribatti D: Angiogenesis in multiple myeloma. Chem Immunol Allergy 99: 180-196, 2014.
7. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ and Greipp PR: Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 8: 2210-2216, 2002.
8. Negaard HF, Iversen N, Bowitz-Lothe IM, Sandset PM, Steinsvik B, Ostenstad B and Iversen PO: Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia 23: 162-169, 2009.
9. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI and Anderson KC: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15: 1950-1961, 2001.
10. Folkman J: Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat Med 1: 27-31, 1995.
11. Ferrara, N, Gerber, HP and LeCouter, J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
12. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G and Rajkumar SV; International Myeloma Working Group: International uniform response criteria for multiple myeloma. Leukemia 20: 1467-1473, 2006.
13. D'Amato RJ, Loughnan MS, Flynn E and Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085, 1994.
14. Kumar S, Witzig TE, Dispenzieri A, Lacy MQ, Wellik LE, Fonseca R, Lust JA, Gertz MA, Kyle RA, Greipp PR and Rajkumar SV: Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia 18: 624-627, 2004.
15. Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW, Hughes CC, Stirling DI, Schafer PH and Bartlett JB: The anticancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 77: 78-86, 2009.
16. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J and Anderson KC: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100: 3063-3067, 2002.
17. Maffei R, Fiorcari S, Bulgarelli J, Rizzotto L, Martinelli S, Rigolin GM, Debbia G, Castelli I, Bonacorsi G, Santachiara R, Forconi F, Rossi D, Laurenti L, Palumbo GA, Vallisa D, Cuneo A, Gaidano G, Luppi M and Marasca R: Endothelium-mediated survival of leukemia cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. Exp Hematol 42: 126-136, 2014.
18. Shin DH, Chun YS, Lee DS, Huang LEand Park W: Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIHmediated repression of hypoxia-inducible factor-1. Blood 111: 3131-3136, 2008.
19. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C and McConkey DJ: Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Molecular Cancer Therapeutics 2: 835-843, 2003.
20. Pour L, Svachova H, Adam Z, Almasi M, Buresova L, Buchler T, Kovarova L, Nemec P, Penka M, Vorlicek J and Hajek R: Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann Hematol 89: 385-389, 2010.
21. Pappa CA, Alexandrakis MG, Boula A, Psarakis FE, Kolovou A, Bantouna V, Stavroulaki E and Tsirakis G: Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients. Hematol Oncol 31: 201-205, 2013.
22. Cibeira MT, Rozman M, Segarra M, Lozano E, Rosiñol L, Cid MC, Filella X and Bladé J: Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. Cytokine 41: 244-253, 2008.
23. Sessa C, Guibal A, Del Conte G and Rüegg C: Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: Tools or decorations? Nat Clin Pract Oncol 5: 378-391, 2008.
24. Pircher A, Hilbe W, Heidegger I, Drevs J, Tichelli A and Medinger M: Biomarkers in tumor angiogenesis and antiangiogenic therapy. Int J Mol Sci 12: 7077-7099, 2011.
25. Ebos JM, Lee CR and Kerbel RS: Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 15: 5020-5025, 2009.